IL-23 inhibitor monoclonal antibody

This page covers all IL-23 inhibitor monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-23 p19 subunit, IL-23 (p19 subunit), IL-23 (interleukin-23), p19 subunit.

Targets

IL-23 p19 subunit · IL-23 (p19 subunit) · IL-23 (interleukin-23), p19 subunit

Marketed (9)

• Mirikizumab - Intravenous (IV) · University of North Carolina, Chapel Hill · Immunology
  Mirikizumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.
• Guselkumab (GUS) · Second Affiliated Hospital, School of Medicine, Zhejiang University · Immunology/Dermatology
  Guselkumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.
• Anti-IL12/23 or anti-IL23 - Risankizumab · University of Calgary · Immunology
  Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway to reduce inflammatory immune responses.
• Risankizumab (RISA) · Caja Costarricense de Seguro Social · Immunology
  Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
• Injections of tildrakizumab · Sun Pharmaceutical Industries Limited · Immunology/Dermatology
  Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.
• Mirikizumab (MIR) · Alimentiv Inc. · Immunology / Gastroenterology
  Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in immune-mediated diseases.
• Mirikizumab - SC · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Immunology / Gastroenterology
  Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.
• SKYRIZI · Chong Kun Dang Pharmaceutical · Immunology/Dermatology
  SKYRIZI (risankizumab) is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
• Mirikizumab - IV · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Immunology / Gastroenterology
  Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.

Phase 2 pipeline (1)

• CNTO 1959 · Janssen Pharmaceutical K.K. · Immunology
  CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses.